TYRA
NASDAQTyra Biosciences Inc.
Price$37.62+1.89 (+5.29%)
01:30 PM07:45 PM
News · 26 weeks50+43%
2025-11-022026-04-26
Mix3290d
- Other10(31%)
- SEC Filings9(28%)
- Insider7(22%)
- Analyst5(16%)
- Leadership1(3%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tyra Biosciences Inc.SCHEDULE 13G/A - Tyra Biosciences, Inc. (0001863127) (Subject)
- INSIDERSEC Form 4 filed by Dable Habib J4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
- INSIDERSEC Form 3 filed by new insider Dable Habib J3 - Tyra Biosciences, Inc. (0001863127) (Issuer)
- SECSEC Form DEFA14A filed by Tyra Biosciences Inc.DEFA14A - Tyra Biosciences, Inc. (0001863127) (Filer)
- SECSEC Form DEF 14A filed by Tyra Biosciences Inc.DEF 14A - Tyra Biosciences, Inc. (0001863127) (Filer)
- SECSEC Form 8-K filed by Tyra Biosciences Inc.8-K - Tyra Biosciences, Inc. (0001863127) (Filer)
- PRTyra Biosciences Announces Appointment of Habib Dable to its Board of Directors-Seasoned biopharmaceutical leader brings deep commercial and strategic expertise to support TYRA's next phase of growth-CARLSBAD, Calif., April 17, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the appointment of Habib Dable to its Board of Directors.Mr. Dable brings more than 30 years of leadership experience across the global biopharmaceutical industry, including deep expertise in building and scaling blockbuster franchises and guiding companies through transformative growth."As TY
- ANALYSTGuggenheim initiated coverage on Tyra Biosciences with a new price targetGuggenheim initiated coverage of Tyra Biosciences with a rating of Buy and set a new price target of $54.00
- SECSEC Form SCHEDULE 13G filed by Tyra Biosciences Inc.SCHEDULE 13G - Tyra Biosciences, Inc. (0001863127) (Subject)
- ANALYSTCanaccord Genuity initiated coverage on Tyra Biosciences with a new price targetCanaccord Genuity initiated coverage of Tyra Biosciences with a rating of Buy and set a new price target of $50.00
- INSIDERSEC Form 3 filed by new insider Rueb Yuliya3 - Tyra Biosciences, Inc. (0001863127) (Issuer)
- SECSEC Form 8-K filed by Tyra Biosciences Inc.8-K - Tyra Biosciences, Inc. (0001863127) (Filer)
- INSIDERSEC Form 4 filed by Kaplan Gilla4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
- SECSEC Form 144 filed by Tyra Biosciences Inc.144 - Tyra Biosciences, Inc. (0001863127) (Subject)
- SECSEC Form 144 filed by Tyra Biosciences Inc.144 - Tyra Biosciences, Inc. (0001863127) (Subject)
- INSIDERChief Financial Officer Fuhrman Alan was granted 1,376 shares, increasing direct ownership by 9% to 16,164 units (SEC Form 4)4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
- INSIDERPresident and CEO Harris Todd was granted 1,463 shares, increasing direct ownership by 0.11% to 1,358,631 units (SEC Form 4)4 - Tyra Biosciences, Inc. (0001863127) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Tyra Biosciences Inc.SCHEDULE 13D/A - Tyra Biosciences, Inc. (0001863127) (Subject)
- SECSEC Form 8-K filed by Tyra Biosciences Inc.8-K - Tyra Biosciences, Inc. (0001863127) (Filer)
- SECSEC Form 10-K filed by Tyra Biosciences Inc.10-K - Tyra Biosciences, Inc. (0001863127) (Filer)
- SECTyra Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Tyra Biosciences, Inc. (0001863127) (Filer)
- PRTyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights- Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -- Interim Ph2 data readouts on track: SURF302 expected by end of 1H'26 and BEACH301 in 2H '26 -- Cash, cash equivalents and marketable securities of $256.0 million at Q4 2025; runway through at least 2027 -CARLSBAD, Calif., March 2, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the fourth quarter and full-year ended Dece
- ANALYSTCantor Fitzgerald initiated coverage on Tyra BiosciencesCantor Fitzgerald initiated coverage of Tyra Biosciences with a rating of Overweight
- PRTyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers SymposiumCARLSBAD, Calif., Feb. 23, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that two abstracts have been accepted for presentation at the 2026 ASCO® Genitourinary (GU) Cancers Symposium (ASCO GU). The meeting is being held February 26-28, 2026, in San Francisco, California.Details of the poster presentations are below:Title: "ctDNA monitoring of FGFR3-altered metastatic urothelial cancer treated with dabogratinib (formerly TYRA-300) in the SURF301 trial"Abstract Number: 809Session: Poste
- SECSEC Form SCHEDULE 13G filed by Tyra Biosciences Inc.SCHEDULE 13G - Tyra Biosciences, Inc. (0001863127) (Subject)